August 3 2013 – Ambrisentan found ineffective against idiopathic pulmonary fibrosis

1. Ambrisentan is ineffective in delaying disease progression in idiopathic pulmonary fibrosis (IPF).

2. Compared to placebo, Ambrisentan is associated with increased risk of disease progression and respiratory hospitalization.

Evidence rating level: 1 (Excellent)

Study rundown: Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive form of fibrotic interstitial lung disease with unknown etiology. IPF is a diagnosis of exclusion, and has a median survival of 3 years after diagnosis. There are no approved drug therapies in the US that have been repeatedly proven efficacious. Therefore, there is a great deal of interest in potential therapies for IPF.

Read the entire article at:

http://www.2minutemedicine.com/ambrisentan-found-ineffective-against-idiopathic-pulmonary-fibrosis/

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

 

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Lung Cancer, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , | Leave a comment

July 29 2013 – UVM hosts conference on revolutionary cell therapies to treat deadly lung diseases

On Monday, July 29, 2013, leading lung disease researchers from around the globe will participate in the fifth biennial “Stem Cells and Cell Therapies in Lung Biology Conference” at the University of Vermont (UVM). Since the meeting’s initiation eight years ago by UVM Professor of Medicine and lung specialist Daniel Weiss, M.D., Ph.D., the field has achieved a number of milestones, including promising strides in the area of bioengineering new lungs. More than 150 participants are expected to attend the invitation-only conference, which takes place at the Sheraton Burlington Hotel and Conference Center on July 29 and at the Dudley H. Davis Center at UVM July 30 through August 1, 2013.

Lung diseases, and especially chronic obstructive pulmonary disease (COPD), which includes conditions such as emphysema and chronic bronchitis, are increasing in prevalence, with COPD predicted to be the third leading cause of death worldwide by the year 2020. With a reported $49.9 billion in related health care costs in 2009, the need to both prevent disease and identify new treatments is critical.

Read the entire article at:

http://vtdigger.org/2013/07/28/uvm-hosts-conference-on-revolutionary-cell-therapies-to-treat-deadly-lung-diseases/

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

July 15 2013 – Compugen Announces US Patent Allowance for Drug Candidate Recently Presented at 2013 American Thoracic Society Meeting

Compugen Ltd. (NASDAQ: CGEN [FREE Stock Trend Analysis]) announced today that the  company has received an Issue Notification from the U.S. Patent and Trademark  Office for a patent application covering the company’s drug candidate  CGEN-25009. CGEN-25009 is intended for the treatment of idiopathic pulmonary  fibrosis, a devastating disease with no current effective treatment. This novel  peptide agonist of the relaxin receptor was the subject of a recent presentation  by Dr. Daniel Kass, from the University of Pittsburgh (“Pitt”), at the 2013  American Thoracic Society Conference.

In his presentation, Dr. Kass, Assistant Professor of Medicine at Pitt and  Assistant Director for Novel Therapeutics and Translational Research at The  Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease at the  University of Pittsburgh Medical Center, presented experimental data  demonstrating that CGEN-25009 protects mice from bleomycin-induced pulmonary  fibrosis. In this model, CGEN-25009 treatment reduced lung fibrosis as  determined by collagen deposition in both preventive and therapeutic  administration regimens.

Read more: http://www.benzinga.com/news/13/07/3751856/compugen-announces-us-patent-allowance-for-drug-candidate-recently-presented-at-2#ixzz2gCuFeKai

Read the entire article at:

http://www.benzinga.com/news/13/07/3751856/compugen-announces-us-patent-allowance-for-drug-candidate-recently-presented-at-2#ixzz2dlvECyB8

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Long Fibrose, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

July 11 2013 – ProMetic’s Lead Drug Candidate, PBI-4050, on Track to Enter Clinical Trial Program in September 2013

LAVAL, QUEBEC–(Marketwired – July 11, 2013) – ProMetic Life Sciences Inc. (TSX:PLI) (OTCQX:PFSCF), (“ProMetic” or the “Corporation”) announced today that its lead drug candidate PBI-4050, is on track to enter the clinical trial program starting in September 2013. During the first half of 2013, the Corporation has systematically executed on all key activities required to enable the initiation of the clinical trials.

The manufacturing process for its orally active anti-fibrotic lead drug candidate has been successfully scaled up in an FDA and EMA approved facility. The required GMP material has been delivered to advance the toxicology program necessary to enable the commencement of the clinical trials. Throughout the preclinical program, PBI-4050 has demonstrated efficacy with a remarkable safety profile. This is expected to be further confirmed in the on-going toxicology studies being performed by a certified contract research organisation (“CRO”).

“The recently presented data on PBI-4050 confirms its potential as a novel therapy to inhibit inflammation and fibrosis which underlies most progressive chronic renal diseases” stated Dr Raymond Hakim, MD, PhD, a kidney specialist who until recently was the Chief Medical Officer of one of the largest provider of renal services in the US and a new member of ProMetic’s Board of Directors. “Diabetes further accelerate the loss of kidney function in patients with CKD, and the extensive PBI-4050 preclinical data generated suggest that this patient population would greatly benefit from this therapeutic approach” added Dr Hakim.

Read the entire article at: http://online.wsj.com/article/PR-CO-20130711-904453.html?mod=googlenews_wsj

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

July 7 2013 – University of Washington’s first double lung transplant doing great 2 decades later

The first person to get a double lung transplant at the University of Washington is still breathing strong 20 years later.

Ken Price had been living with cystic fibrosis since he was 1 year old, KOMO-TV reports. He was the first cystic fibrosis patient at the University of Washington Medical Center to receive a double lung transplant.

In the 20 years since then, Price and his lungs have won tennis tournaments, rode his bike from Seattle to Portland eight times and run a marathon.

Read the entire article at: http://www.foxnews.com/health/2013/07/05/uw-first-double-lung-transplant-still-breathing-fine-after-20-years/

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

July 2 2013 – New procedure to treat acid reflux can prevent chronic rejection in lung transplant patients

A Loyola University Medical Center study suggests that a procedure to treat acid reflux could help prevent chronic rejection in lung transplant patients.

The study also found that certain proteins found in lung fluid can help predict whether a patient’s transplanted lung is more likely to fail.

Results are published in the July, 2013 issue of the Journal of the American College of Surgeons. Authors are P. Marco Fisichella, MD, FACS (first author), Christopher S. Davis, MD, MPH; Erin Lowery, MD, MS; Luis Ramirez, BS; Richard L. Gamelli, MD, FACS and Elizabeth J. Kovacs, PhD.

Read the entire article at:

http://www.news-medical.net/news/20130630/New-procedure-to-treat-acid-reflux-can-prevent-chronic-rejection-in-lung-transplant-patients.aspx

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

 

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

June 28 2013 – Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials

Summary

Background

Abnormal acid gastro-oesophageal reflux is common in patients with idiopathic pulmonary fibrosis (IPF) and is considered a risk factor for development of IPF. Retrospective studies have shown improved outcomes in patients given anti-acid treatment. The aim of this study was to investigate the association between anti-acid treatment and disease progression in IPF.

Read the entire article at:

http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(13)70105-X/fulltext

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

 

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

June 24 2013 – Verona Pharma confirms 1st patient dosed with VRP700

StockMarketWire.com – Verona Pharma said the first patient in a clinical trial to further evaluate the efficacy of VRP700 as a novel treatment for chronic severe cough has been dosed with the drug.  It was anticipated that data from this clinical trial will be available in the first half of 2014.

In this randomised, double-blind, placebo-controlled crossover study, a total of 20 adults with idiopathic pulmonary fibrosis (IPF) will be treated, by inhalation, with a single nebulized dose of VRP700.

Read the entire article at:

http://www.stockmarketwire.com/article/4618764/Verona-Pharma-confirms-1st-patient-dosed-with-VRP700.html

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

 

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , , , | Leave a comment

June 12 2013 – GPs urged to suspect pulmonary fibrosis in older patients with persistent cough

 

 

NICE is urging GPs to be alert to the clinical features of idiopathic pulmonary fibrosis (IPF) and refer patients who may have the condition promptly, in new guidance aimed at speeding up diagnosis and treatment for the condition.

In the first NICE guidance for IPF, says GPs should suspect the disease in patients aged 45 or older who present with a persistent cough, breathlessness and bilateral inspiratory crackles and ensure that patients are referred on for chest X-rays and specialist care.

Read the entire article at:

http://www.pulsetoday.co.uk/clinical/therapy-areas/respiratory-medicine/gps-urged-to-suspect-pulmonary-fibrosis-in-older-patients-with-persistent-cough/20003259.article#.UjDpzcvD9EY

For more information about Idiopathic Pulmonary Fibrosis please visit our website www.ipftoday.com and don’t forget to like us on www.facebook.com/IPFToday

 

 

 

 

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , , , | Leave a comment

June 7 2013 – Genoa, McMaster University reveal findings of GP-101 in pulmonary fibrosis treatment

US-based inhaled medicines provider Genoa Pharmaceuticals in collaboration with McMaster University has demonstrated advantages of the inhaled aerosol pirfenidone (GP-101) in the treatment of pulmonary fibrosis.

The findings showed that small inhaled doses yielding high peak, short duration lung pirfenidone concentrations provide statistically greater anti-fibrotic efficacy than higher oral doses resulting in low peak drug exposure by using the in vivo model of bleomycin-induced pulmonary fibrosis.

Genoa Pharmaceuticals founder, president and chief scientific officer Mark Surber said for IPF treatment to be successful, sufficient drug must first be delivered to the lung.

Read the entire article at:

http://drugdelivery.pharmaceutical-business-review.com/news/genoa-mcmaster-university-reveal-findings-of-gp-101-in-pulmonary-fibrosis-treatment-070613

For more information about Idiopathic Pulmonary Fibrosis please visit: www.ipftoday.com

 

Posted in Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, IPF, Medical, Pulmonary Fibrosis, Uncategorized | Tagged , , , , , , , , , , , , , | Leave a comment